213 related articles for article (PubMed ID: 26231318)
1. Bicytopenia, especially thrombocytopenia in hemodialysis and non-hemodialysis patients treated with linezolid therapy.
Kato H; Hamada Y; Hagihara M; Hirai J; Yamagishi Y; Matsuura K; Mikamo H
J Infect Chemother; 2015 Oct; 21(10):707-12. PubMed ID: 26231318
[TBL] [Abstract][Full Text] [Related]
2. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.
Hanai Y; Matsuo K; Ogawa M; Higashi A; Kimura I; Hirayama S; Kosugi T; Nishizawa K; Yoshio T
J Infect Chemother; 2016 Aug; 22(8):536-42. PubMed ID: 27321773
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases.
Choi GW; Lee JY; Chang MJ; Kim YK; Cho Y; Yu YM; Lee E
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):228-234. PubMed ID: 30171804
[TBL] [Abstract][Full Text] [Related]
5. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.
Ichie T; Suzuki D; Yasui K; Takahashi H; Matsuda M; Hayashi H; Sugiura Y; Sugiyama T
J Clin Pharm Ther; 2015 Jun; 40(3):279-84. PubMed ID: 25732525
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia Associated with Linezolid Therapy in Solid Organ Transplant Recipients: A Retrospective Cohort Study.
Tessier JM; Puzio T; Young A; Wolfe L; Han J; Duane TM
Surg Infect (Larchmt); 2015 Aug; 16(4):361-7. PubMed ID: 26207396
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients.
Hirano R; Sakamoto Y; Tachibana N; Ohnishi M
Int J Clin Pharm; 2014 Aug; 36(4):795-9. PubMed ID: 24913359
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia.
Onita T; Ishihara N; Ikebuchi A; Yano T; Nishimura N; Tamaki H; Ikawa K; Morikawa N; Naora K
J Clin Pharm Ther; 2022 Dec; 47(12):2041-2048. PubMed ID: 35893441
[TBL] [Abstract][Full Text] [Related]
9. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
10. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid.
Zhang YM; Yu W; Zhou N; Li JZ; Xu LC; Xie ZY; Lu YF; Li LJ
Hepatobiliary Pancreat Dis Int; 2015 Jun; 14(3):287-92. PubMed ID: 26063030
[TBL] [Abstract][Full Text] [Related]
11. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study.
Kim HS; Lee E; Cho YJ; Lee YJ; Rhie SJ
J Clin Pharm Ther; 2019 Feb; 44(1):84-90. PubMed ID: 30243033
[TBL] [Abstract][Full Text] [Related]
12. Linezolid-induced haematological toxicity.
Moraza L; Leache L; Aquerreta I; Ortega A
Farm Hosp; 2015 Nov; 39(6):320-6. PubMed ID: 26618376
[TBL] [Abstract][Full Text] [Related]
13. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin.
Hiraki Y; Tsuji Y; Matsumoto K; Morita K; Kamimura H; Karube Y
Am J Med Sci; 2011 Dec; 342(6):456-60. PubMed ID: 21681075
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination.
Kaya Kılıç E; Bulut C; Sönmezer MÇ; Ozel Ö; Ataman Hatipoğlu Ç; Tuncer Ertem G; Tülek N; Kınıklı S
J Infect Dev Ctries; 2019 Oct; 13(10):886-891. PubMed ID: 32084018
[TBL] [Abstract][Full Text] [Related]
15. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy.
Takahashi Y; Takesue Y; Nakajima K; Ichiki K; Tsuchida T; Tatsumi S; Ishihara M; Ikeuchi H; Uchino M
J Infect Chemother; 2011 Jun; 17(3):382-7. PubMed ID: 21127934
[TBL] [Abstract][Full Text] [Related]
16. Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.
Jones SJ; Nichols KR; DeYoung HL; Cox EG; Knoderer CA
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):272-5. PubMed ID: 26407433
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience of linezolid in bone marrow transplantation patients.
Hogan HL; Hachem RY; Neuhauser M; Raad II; Coyle E
J Pharm Pract; 2010 Aug; 23(4):352-7. PubMed ID: 21507835
[TBL] [Abstract][Full Text] [Related]
18. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.
Wu VC; Wang YT; Wang CY; Tsai IJ; Wu KD; Hwang JJ; Hsueh PR
Clin Infect Dis; 2006 Jan; 42(1):66-72. PubMed ID: 16323094
[TBL] [Abstract][Full Text] [Related]
19. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
[TBL] [Abstract][Full Text] [Related]
20. Linezolid-associated thrombocytopenia.
Lam S
Consult Pharm; 2012 Jul; 27(7):504-8. PubMed ID: 22910131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
